{"product_id":"radiopharmaceutical-radioligand-therapy-markets","title":"Radiopharmaceutical \u0026 Radioligand Therapy Markets","description":"\u003cp\u003e\u003cstrong\u003eRadiopharmaceutical \u0026amp; Radioligand Therapy: Market Forecast, Competitive Landscape and Strategic Opportunities, 2027–2031\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlobal forecasts by indication, isotope, target, targeting vector and treatment setting, with country and regional breakouts and 20 company profiles.\u003c\/p\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCRLT\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eOur Take\u003c\/h3\u003e\n\u003cp\u003eRadioligand therapy is moving earlier. The market grows from $3,910.0 million in 2026 to $10,800.0 million in 2031, at 22.5% a year. Pluvicto's approval in hormone-sensitive prostate cancer on 31 July 2026 lifts Earlier-Line Metastatic use from $879.8 million to $5,130.0 million, overtaking late-line use, while alpha emitters rise from about 10% to 22% of the market after the first positive Phase 3 trial of an actinium-225 drug.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCRLT_Key_Graphic.png?v=1793236680\" alt=\"Radioligands move earlier: radiopharmaceutical and radioligand therapy market by treatment setting, 2026 to 2031\" style=\"width:100%;height:auto;\"\u003e\u003c\/p\u003e\n\u003ch3\u003eSituation Analysis: what is really happening\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePluvicto moves earlier. \u003c\/strong\u003eThe FDA approved Pluvicto in PSMA-positive hormone-sensitive prostate cancer on 31 July 2026. Pluvicto sold $1,994 million in 2025 and $1,967 million in the first nine months of 2026, up 42%. Prostate Cancer grows from $2,866.0 million to $6,696.0 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eActinium arrives. \u003c\/strong\u003eBristol Myers Squibb's RYZ101 met its Phase 3 endpoint in neuroendocrine tumours in October 2026, the first pivotal win for an actinium product. Actinium-225 grows from $3.9 million to $1,134.0 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLutathera faces copies. \u003c\/strong\u003eCurium's Bexlutry and Lantheus's Bravnetsa were approved in September 2026, and Curium agreed to buy Lantheus for up to $8.0 billion. Neuroendocrine Tumours still grow 20.5% a year, from $957.9 million to $2,430.0 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing decides approvals. \u003c\/strong\u003eITM received a complete response letter for ITM-11 in August 2026 for manufacturing reasons alone, and Orano Med and Sanofi reset the lead-212 programme AlphaMedix after delayed side effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe US leads, China grows fastest. \u003c\/strong\u003eThe United States accounts for 65.1% of revenue in 2026, while China grows from $209.2 million to $697.2 million, at 27.2% a year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompany Analysis: who is positioned, who is exposed\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovartis: \u003c\/strong\u003ePluvicto and Lutathera earn about nine dollars in every ten spent on therapeutic radiopharmaceuticals in 2026. Novartis must move Pluvicto earlier and bring actinium forward before copies and challengers erode its franchise.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBristol Myers Squibb: \u003c\/strong\u003eRYZ101 (Ac-225-DOTATATE), acquired with RayzeBio, met its endpoint in the Phase 3 ACTION-1 trial after lutetium therapy, putting BMS first among the alpha challengers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAstraZeneca: \u003c\/strong\u003eAZD2265, an actinium-225 PSMA drug, is in the Phase 3 VECTRA-01 trial in prostate cancer after lutetium PSMA therapy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCurium: \u003c\/strong\u003eBexlutry, the first approved copy of Lutathera, and the planned acquisition of Lantheus give it isotope production, two radioligand equivalents and a Lu-177 PSMA candidate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBayer: \u003c\/strong\u003eXofigo is in long-term decline, and 225Ac-PSMA-Trillium is not expected to launch before the end of the decade.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eITM: \u003c\/strong\u003eOne of the largest suppliers of non-carrier-added Lu-177; its first therapy, ITM-11, was delayed by a complete response letter, and ITM plans to resubmit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlus 14 more company profiles covering Eli Lilly, Sanofi, Lantheus, Telix, Orano Med and clinical-stage developers.\u003c\/p\u003e\n\u003ch3\u003eQuestions this report answers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eHow fast will Pluvicto move into hormone-sensitive prostate cancer?\u003c\/li\u003e\n\u003cli\u003eWhich actinium-225 and lead-212 products will reach the market by 2031?\u003c\/li\u003e\n\u003cli\u003eHow quickly will copies of Lutathera erode prices in neuroendocrine tumours?\u003c\/li\u003e\n\u003cli\u003eCan isotope supply and manufacturing keep up with demand?\u003c\/li\u003e\n\u003cli\u003eWhich new targets, such as FAP and Nectin-4, will open breast, lung and other cancers?\u003c\/li\u003e\n\u003cli\u003eHow large will China become, and who will lead there?\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat’s inside\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e193 pages, 23 chapters, 53 tables and 50 figures\u003c\/li\u003e\n\u003cli\u003e20 company profiles with technology, pipeline, strategy and risks\u003c\/li\u003e\n\u003cli\u003eForecasts 2027–2031 from a 2026 base (actual) year, by indication, isotope, target, targeting vector and treatment setting, for 14 countries and regions\u003c\/li\u003e\n\u003cli\u003eApproved product benchmarks, Pluvicto and Lutathera sales, and ten market-moving developments from 2026\u003c\/li\u003e\n\u003cli\u003eClinical pipeline, combinations, isotope supply and manufacturing, regulation and reimbursement, the Lutathera patent cliff, and a China ecosystem chapter\u003c\/li\u003e\n\u003cli\u003eDelivered as 3 files: full report PDF, Situation Analysis PDF, and Excel workbook of all charts and tables\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCRLT_1126_Table_of_Contents.pdf?v=1793236680\" target=\"_blank\" rel=\"noopener\"\u003eDownload the Table of Contents (PDF)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCRLT\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eWho buys this report\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBusiness development teams: \u003c\/strong\u003etrack which isotopes, targets and vectors are winning, and who leads each.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestors and equity analysts: \u003c\/strong\u003emodel Pluvicto's earlier-line growth, the arrival of actinium-225 and the Curium–Lantheus deal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadioligand developers: \u003c\/strong\u003echoose the targets, isotopes and treatment settings with the most room to grow.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotope producers and manufacturers: \u003c\/strong\u003esize demand for lutetium-177, actinium-225 and lead-212 and the capacity being built.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLicences and support\u003c\/h3\u003e\n\u003cp\u003eYour order is delivered to your inbox immediately. Every licence includes unlimited questions to the analyst and custom data breakouts, including any country not shown. Single User, Five User and Enterprise licences contain the same report; they differ only in how many people may use it.\u003c\/p\u003e\n\u003ch3\u003eAbout the author\u003c\/h3\u003e\n\u003cp\u003eGreg Powell, B.Sc., M.B.A., has worked in laboratory testing and management for more than 20 years, with executive training at Harvard Business School and the Burke Institute.\u003c\/p\u003e","brand":"OncoPharma Insights","offers":[{"title":"Single User","offer_id":67912497987663,"sku":null,"price":6995.0,"currency_code":"USD","in_stock":true},{"title":"Five User","offer_id":67912498020431,"sku":null,"price":9995.0,"currency_code":"USD","in_stock":true},{"title":"Enterprise License","offer_id":67912498053199,"sku":null,"price":13995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCRLT_1126_covercap.png?v=1793236680","url":"https:\/\/oncopharmainsights.com\/products\/radiopharmaceutical-radioligand-therapy-markets","provider":"OncoPharma Insights","version":"1.0","type":"link"}